Trade Blueprint Medicines Corporation - BPMC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.43 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 94.98 |
| Open | 93.63 |
| 1-Year Change | 6.63% |
| Day's Range | 93.63 - 96.8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | 96.10 | 4.39 | 4.79% | 91.71 | 96.80 | 91.71 |
| Dec 16, 2024 | 94.98 | 3.55 | 3.88% | 91.43 | 95.91 | 90.76 |
| Dec 13, 2024 | 92.73 | 0.32 | 0.35% | 92.41 | 93.44 | 91.03 |
| Dec 12, 2024 | 91.79 | -1.74 | -1.86% | 93.53 | 94.66 | 90.15 |
| Dec 11, 2024 | 94.32 | -0.17 | -0.18% | 94.49 | 96.39 | 93.07 |
| Dec 10, 2024 | 95.14 | 0.97 | 1.03% | 94.17 | 97.23 | 94.17 |
| Dec 9, 2024 | 94.36 | -0.54 | -0.57% | 94.90 | 96.70 | 91.58 |
| Dec 6, 2024 | 95.81 | 1.77 | 1.88% | 94.04 | 96.89 | 93.22 |
| Dec 5, 2024 | 94.59 | 0.02 | 0.02% | 94.57 | 96.15 | 93.48 |
| Dec 4, 2024 | 96.11 | 3.30 | 3.56% | 92.81 | 98.39 | 92.65 |
| Dec 3, 2024 | 96.37 | 1.88 | 1.99% | 94.49 | 96.75 | 94.49 |
| Dec 2, 2024 | 97.13 | 1.53 | 1.60% | 95.60 | 97.88 | 95.01 |
| Nov 29, 2024 | 95.86 | 1.38 | 1.46% | 94.48 | 97.84 | 94.35 |
| Nov 27, 2024 | 94.97 | 0.21 | 0.22% | 94.76 | 95.34 | 92.16 |
| Nov 26, 2024 | 94.21 | 2.11 | 2.29% | 92.10 | 95.11 | 91.48 |
| Nov 25, 2024 | 93.73 | 0.40 | 0.43% | 93.33 | 95.75 | 92.76 |
| Nov 22, 2024 | 94.08 | -0.57 | -0.60% | 94.65 | 98.13 | 93.54 |
| Nov 21, 2024 | 96.56 | 1.83 | 1.93% | 94.73 | 97.98 | 91.62 |
| Nov 20, 2024 | 94.70 | 0.53 | 0.56% | 94.17 | 94.91 | 91.69 |
| Nov 19, 2024 | 94.51 | 6.88 | 7.85% | 87.63 | 95.15 | 87.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Blueprint Medicines Corporation Company profile
About Blueprint Medicines Corp
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com